GlassScriptPhysician profile
Thomas Michalsen
NPI 1114947876
$2,850.36
in general payments reported to CMS, 2019-2025
24 companies · $560 in 2025
The $560 reported for 2025 was more than what 85% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $133 · 2021: $182 · 2022: $327 · 2023: $492 · 2024: $382 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,434.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $789.99 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $270.04 | 2019-2025 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.34 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $249.98 | 2023 | Nuplazid |
| Sunovion Pharmaceuticals INC. | $178.16 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $164.84 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $145.65 | 2022-2023 | Spravato |
| Amarin Pharma, INC. | $129.26 | 2019 | |
| Novartis Pharmaceuticals Corporation | $119.49 | 2019 | |
| Merck Sharp & Dohme LLC | $87.33 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.64 | 2021 | |
| Genzyme Corporation | $43.60 | 2020 | |
| Cipher Pharmaceuticals US LLC | $43.08 | 2025 | Natroba, Spinosad |
| Biohaven Pharmaceuticals, INC. | $39.85 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $38.58 | 2024-2025 | Austedo Xr, Austedo Xr |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $37.93 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.92 | 2022 | |
| Novo Nordisk INC | $31.94 | 2020 | |
| Abbvie INC. | $28.47 | 2022-2023 | |
| Pfizer INC. | $28.12 | 2023 | |
| Nevro Corp. | $23.10 | 2019 | |
| Smith+Nephew, INC. | $22.68 | 2021 | |
| Glaxosmithkline, LLC. | $20.14 | 2019 | |
| Esperion Therapeutics, INC. | $18.23 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Michalsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.